Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006618309
Mon, 12.12.2022
MEDIQON Group AG
Today, the Management Board (with the approval of the Supervisory Board) of MEDIQON Group AG (ISIN: DE0006618309) resolved a capital increase from authorized capital with the exclusion of subscription rights by issuing up to 10% of its registered share capital of EUR 14,999,333.00. The Company expects to raise EUR 10 to 20 million.
The new shares w [ … ]
Mon, 12.12.2022
MEDIQON Group AG
Today, the Management Board (with the approval of the Supervisory Board) of MEDIQON Group AG (ISIN: DE0006618309) resolved a capital increase from authorized capital with the exclusion of subscription rights by issuing up to 10% of its registered share capital of EUR 14,999,333.00. The Company expects to raise EUR 10 to 20 million.
The new shares w [ … ]
Fri, 30.09.2022
MEDIQON Group AG
MEDIQON Group AG: Interim Report 2022 – Positive development of the group in the first half of 2022
Today, MEDIQON Group AG published its Interim Report 2022.
In the first half of 2022, 3 additional operating companies became part of the group. As of June 30, 2022, a total of 22 operating companies belong to the group, two of which are minority hol [ … ]
Fri, 30.09.2022
MEDIQON Group AG
MEDIQON Group AG: Interim Report 2022 – Positive development of the group in the first half of 2022
Today, MEDIQON Group AG published its Interim Report 2022.
In the first half of 2022, 3 additional operating companies became part of the group. As of June 30, 2022, a total of 22 operating companies belong to the group, two of which are minority hol [ … ]
Tue, 24.05.2022
MEDIQON Group AG
MEDIQON Group AG: Annual Report 2021 published – Group growth continued successfully in the 2021 fiscal year
Today, MEDIQON Group AG published its Annual report 2021. The group’s growth continued successfully in the financial year.
In 2021, 10 additional operating companies became part of the group. At the end of the fiscal year, 20 operating com [ … ]
Wed, 13.04.2022
MEDIQON Group AG
MEDIQON Group AG: Investor Base strengthened with 2022 Rights Issue
Further to the 04/07/2022 ad-hoc release, MEDIQON Group AG today announces the successful placing of the 2022 rights issue.
The company raised EUR 41.6m by issuing 3,999,820 new shares. The rights issue was significantly oversubscribed.
Sator Grove Holdings LLC and Mitch Rales, [ … ]
Thu, 07.04.2022
MEDIQON Group AG
MEDIQON Group AG has successfully placed all new shares from the capital increase with subscription rights resolved on March 15, 2022.
The capital increase is subject to the entry in the commercial register. The share capital of the company will increase from EUR 10,999,513.00 to EUR 14,999,333.00 by issuing to 3,999,820 new shares against cash co [ … ]
Tue, 15.03.2022
MEDIQON Group AG
MEDIQON Group AG: Capital Increase via subscription rights issue resolved
The Management Board of MEDIQON Group AG (ISIN: DE0006618309) today resolved, with the approval of the supervisory board, to increase the share capital of the company from 10,999,513.00 to EUR 14,999,333.00 by issuing up to 3,999,820 new shares against cash distribution wit [ … ]
Mon, 14.03.2022
MEDIQON Group AG
NGC Nachfolgekapital GmbH, a subsidiary of MEDIQON Group AG, entered into a transaction agreement in relation to its subsidiary vetera GmbH
Today, Nordhealth A/S and NGC Nachfolgekapital GmbH, an 80% subsidiary of MEDIQON Group AG agreed that vetera GmbH, an 80% subsidiary of NGC Nachfolgekapital GmbH will become part of the Portfolio of Practice [ … ]
Thu, 24.02.2022
MEDIQON Group AG
MEDIQON Group AG: Group growth continued successfully in the 2021 fiscal year
MEDIQON Group AG once again grew strongly in the 2021 fiscal year. At the end of 2021, a total of 20 operating companies belong to the group - two of them as minority interests.
The gross investment volume as part of the acquisition of majority holdings and the resultin [ … ]